Our strategy
GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company.
We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Explore more on our global website below.
Our portfolio
Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, oncology and immunology.
We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
Our long-term priorities

We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. We’re working to get better at finding them in ways that are faster, more effective, and more predictable. This is reflected in the continued success of our R&D pipeline, which saw significant progress in 2021. Strategic partnerships are critical to opening up new avenues of discovery.
-
Major approvals since 2017
13 -
Potential new vaccines and medicines in Phase 3 and registration in 2017
23 -
Vaccines and medicines in our pipeline
60+

We’re confident in our future. Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery over the next five years. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.
-
Vaccines delivered in 2021
>767mn -
Medicine doses delivered in 2021
1.7bn

Being a responsible business is an integral part of our strategy. We apply our strengths and take action in the areas that can most positively impact patients, society and our people over the long-term. This includes pricing and access, sustainability, global health and health security, diversity, equity and inclusion, product governance and operating standards.
Our culture
At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place where people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here.
Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.